This is a medicine used to treat severe headaches, specifically migraines. It works by constricting blood vessels in the brain to help stop the headache.
Every report comes from a Lived member, sent anonymously.
Have you tried Dihydroergotamine for Migraines?
Dihydroergotamine, often called DHE, is a prescription medicine used to stop a migraine attack that has already started, whether or not the migraine comes with aura (warning symptoms such as flashing lights). Its injectable forms are also approved for attacks of cluster headache, a severe one-sided headache that comes in bouts. DHE does not prevent migraines, and it is not used for hemiplegic migraine or migraine with brainstem aura, rare types that cause weakness or brainstem symptoms. DHE belongs to a group of medicines called ergot alkaloids and is a close chemical relative of ergotamine. Clinicians often consider it when triptans, the most widely used migraine-stopping medicines, have not helped, and for attacks that are severe, long-lasting, present on waking or tied to menstrual periods. It comes in several forms: nasal sprays (Migranal, Trudhesa and generic versions), a nasal powder (Atzumi), a self-injected autoinjector (Brekiya) and a generic injection that can go into a vein, a muscle or under the skin. The nasal products and the autoinjector are approved for adults. The injection was long sold as D.H.E. 45, a brand that has since been discontinued in the US.
During a migraine, the trigeminal nerve system, which carries sensation from the face and head, becomes activated and releases inflammatory chemical messengers around the blood vessels that surround the brain. DHE works mainly by activating a type of serotonin receptor (5-HT1D) found on those blood vessels and on the trigeminal nerve endings. Activating these receptors narrows the vessels and is thought to reduce the release of the inflammatory messengers that sustain the pain. Researchers are not certain which of these two effects matters more. DHE also acts on many other receptors, including ones for noradrenaline and dopamine. That broader activity helps explain side effects such as nausea and the narrowing of blood vessels elsewhere in the body. Because DHE is poorly absorbed when swallowed, it is not given as a pill: it is sprayed or puffed into the nose or injected.
DHE is taken when a migraine starts, not on a schedule. Each product has its own dose and device, so instructions for one do not transfer to another. The older Migranal-type nasal spray is used as one spray in each nostril, repeated 15 minutes later; using more than that for a single attack has not been shown to help. Trudhesa is one spray in each nostril from a device that is assembled and primed before use, and Atzumi is a powder puffed into one nostril. If a dose is needed again, the next one is usually taken at least an hour later, within that product's limits. The Brekiya autoinjector delivers a single 1 mg dose into the thigh, and people can give it to themselves. The generic injection can also be self-injected into a muscle or under the skin after instruction from the prescriber. Intravenous (IV) DHE is given only by a care team, in an emergency department, infusion center or hospital, often after other treatments have failed. For a prolonged migraine that will not break, hospitals sometimes give repeated IV doses over one to three days. Every form has a daily and a weekly maximum, and none is meant for daily use. Prolonged daily use has been linked to fibrosis, a buildup of scar-like tissue around the lungs or at the back of the abdomen. Because DHE can narrow the heart's arteries, a heart evaluation is recommended before the first dose. People with risk factors for heart disease, such as high blood pressure, high cholesterol, smoking, diabetes, obesity, a strong family history, being a man over 40 or having gone through menopause, are advised to take the first dose in a medical setting, sometimes with an ECG (a recording of the heart's electrical activity) afterward.
With the nasal forms, the most common effects are a stuffy or runny nose, nasal irritation, an altered sense of taste, nausea, vomiting, dizziness, sleepiness, a sore throat and diarrhea. If nasal irritation is severe or keeps coming back, the prescriber may pause or stop the product. Injected DHE, and IV DHE in particular, reaches higher levels in the blood quickly, so whole-body effects such as nausea, dizziness, tingling and flushing are more common than with the nasal forms. The serious risks come from DHE narrowing blood vessels outside the head. Numbness or tingling in the fingers or toes, fingers or toes that turn cold, pale or bluish, or muscle pain or weakness in the legs are signs of reduced blood flow: stop using DHE and contact the prescriber right away. Heart attacks, dangerous heart rhythms, strokes and bleeding in the brain have been reported rarely, and some strokes occurred in people who took DHE for symptoms they assumed were migraine. Call 911 for chest pain or pressure, sudden weakness or numbness on one side of the body, trouble speaking, or a sudden, severe headache unlike your usual attacks.
DHE carries a boxed warning from the US Food and Drug Administration (FDA), the agency's most prominent kind of warning, about combining it with strong CYP3A4 inhibitors. CYP3A4 is a liver enzyme that clears DHE from the body. When a medicine blocks it, DHE builds up and can narrow blood vessels severely enough to cut off blood flow to the brain, hands or feet. These combinations must be avoided: certain HIV medicines such as ritonavir, nelfinavir and indinavir; the antibiotics clarithromycin and erythromycin; and the antifungal medicines ketoconazole and itraconazole. Milder blockers, including the antifungal fluconazole, the antidepressants fluoxetine and fluvoxamine, and grapefruit juice, call for caution. Because antibiotics and antifungals are often prescribed quickly for an infection, every prescriber and pharmacist should know that you keep DHE on hand, even if you use it only occasionally. DHE should not be used within 24 hours of a triptan such as sumatriptan, or of another ergot medicine such as ergotamine, because their effects on blood vessels add up. It should not be combined with other medicines that constrict blood vessels and raise blood pressure, and nicotine can make the narrowing worse. DHE is not suitable for people with coronary heart disease or angina, coronary artery spasm, uncontrolled high blood pressure, peripheral artery disease (narrowed arteries in the legs), severe liver or kidney disease, sepsis, recent surgery on blood vessels, or a past allergic reaction to ergot medicines. It should be avoided during pregnancy because it can trigger preterm labor. It may also reduce breast milk supply, and a related drug has caused vomiting, diarrhea and unstable blood pressure in breastfed infants, so the labels advise not breastfeeding during treatment and for 3 days after the last dose.
DHE often eases a migraine within a few hours, and its effect can last up to two days, so relief tends to hold rather than wear off later in the day. Unlike some attack medicines that work best when taken very early, it can still help when used several hours into an attack. Response varies from person to person and between products: in trials of the older nasal spray, the benefit over a placebo differed widely from study to study, and newer nasal devices were designed to deliver the drug more consistently. If one form does not work well, another form or route may. Because DHE treats attacks rather than preventing them, it helps to track how many days a month you use it. Using DHE or other migraine-stopping medicines on 10 or more days a month can lead to medication overuse headache, in which headaches become more frequent or daily. Needing DHE often is a reason to discuss preventive treatment. People who keep using DHE over the years and develop heart risk factors may need periodic heart checkups.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Dihydroergotamine, what you've noticed, or ask the community a question.